54 results about "Tumour volume" patented technology

In a method and system for planning and implementing a selective internal radiation therapy (SIRT), the liver volume and the tumor volume are automatically calculated in a processor by analysis of items segmented from images obtained from the patient using one or more imaging modalities, with the administration of a contrast agent. The volume of therapeutic agent that is necessary to treat the tumor is automatically calculated from the liver volume, the tumor volume, and the body surface area of the patient and the lung shunt percentage for the patient. The therapeutic agent can be administered via respective feeder vessels in respectively different amounts that correspond to the percentage of blood supply to the tumor from the respective feeder vessels, this distribution also being automatically calculated by analysis of one or more parenchymal blood volume (PBV) images.

An apparatus and method for determining a volume of tumor mass destroyed. The present invention includes a temperature probe and a laser probe having a temperature sensor. The laser probe and temperature probe are inserted to measure a temperature of the tumor mass and a temperature of tissue mass surrounding the tumor mass. By determining the volume of tumor mass destroyed, a graphical representation of the volume of tumor mass destroyed is provided whereby real-time visual monitoring of the destruction of the tumor mass is achieved.

A deliverable four dimensional (4D) intensity modulated radiation therapy (IMRT) planning method is disclosed, for delivery using a linear accelerator with a dynamic multi-leaf collimator (DMLC). A 4D computed tomography (CT) scan is used for segmenting tumor anatomy on a reference phase of periodic motion of the tumor. Deformable registration of the 4D CT data is used to generate corresponding anatomical structures on other phases. Preferably, the collimator for each beam position is aligned using the gross tumor volume (GTV) centroid motion corresponding to the periodic motion of the tumor, as determined from the two dimensional (2D) projection of a given beam position. A deliverable IMRT plan is created on the 4D CT image set in which the MLC leaf positions and beam on / off status can vary as a function of respiratory phase by solving a four dimensional optimization problem. The mechanical constraints of the MLC leaves are included in the optimization.

The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.

A nutritional supplement containing fish oil and selenium has been identified that potentiates radiotherapy of tumors in a synergistic fashion. Cotherapy with such a supplement and radiotherapy results in substantially improved reductions in tumor volume of animal models relative to radiotherapy alone, and reduces common side effects such as weight loss, inflammation, and damage to the gastrointestinal tract. Such cotherapy was also found to reduce the incidence of metastasis from the primary implantation site, and to modulate expression of genes associated with apoptosis in tumor cells. A formulation for such a supplement that is both well tolerated and palatable is also provided.

A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, comprising the steps of: A. Providing at least one biological sample originating from said individual at a first point in time; B. Providing at least one biological sample originating from said individual at a second point in time; C. In said at least two biological samples, measuring a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of biomarker presence or concentration; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis; wherein the time period between the first point in time and the second point in time is in the range from 0.5% to 25%, or more preferably in the range from 0.1% to 15%, of a typical tumor volume doubling time of said predefined solid tumor cancer; and the at least one biomarker determined is the same biomarker in each of the biological samples.

A software device that aids the user to evaluate the dose distribution and dose tolerance limits for radiation therapy treatment plans. Radiation therapy treats a desired tumor volume as well as undesired volumes of critical anatomical structures within the patient. The dose volume histogram (DVH) is commonly used to assess the volume of tumor and the volumes of critical structures receiving certain doses. The disclosed invention overlays historical dose statistical information on the dose volume histogram to conveniently enable the user to evaluate the quality of the radiation treatment plan.

A method and apparatus for measuring tumors such as subcutaneous tumors is provided. A device having a flexible membrane is positioned over the tumor and displaced toward the tumor so that the tumor deforms the flexible membrane. Deforming the membrane changes the pressure or volume within a fluid-filled cavity. A gauge measures the change in volume or pressure and the gauge reading correlates with the volume of the tumor.